世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

呼吸器疾患治療薬の世界市場インサイト、2028年までの予測


Global Respiratory Disorders Drugs Market Insights, Forecast to 2028

市場の分析と洞察。呼吸器疾患用薬剤の世界市場 呼吸器疾患治療薬の世界市場規模は、2021年の100万米ドルから2028年には100万米ドルに達すると予測され、2022年から2028年の間にCAGR(年平均成長率)%で推移す... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2022年3月4日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

市場の分析と洞察。呼吸器疾患用薬剤の世界市場
呼吸器疾患治療薬の世界市場規模は、2021年の100万米ドルから2028年には100万米ドルに達すると予測され、2022年から2028年の間にCAGR(年平均成長率)%で推移すると予想されています。
この健康危機による経済変化を十分に考慮し、2021年に呼吸器疾患薬の世界市場の%を占めた経口は、2028年までに100万米ドルの値を示し、COVID-19後の期間に改訂された%のCAGRで成長すると予測されます。一方、病院セグメントは、この予測期間を通して%CAGRに変更されています。

中国の呼吸器障害治療薬の市場規模は2021年に100万米ドル、北米と欧州の呼吸器障害治療薬はそれぞれ100万米ドル、100万米ドルとされています。北米の割合は2021年に%、中国と欧州はそれぞれ%、%で、中国の割合は2028年に%に達すると予測され、分析期間を通じてCAGRは%となっています。日本、韓国、東南アジアはアジアで注目すべき市場であり、今後6年間のCAGRはそれぞれ%、%、%となっています。ヨーロッパの呼吸器疾患治療薬の展望については、ドイツは2028年までに100万米ドルに達すると予測され、予測期間中のCAGRは%です。

本レポートは、業界標準の分析精度と高いデータ整合性により、世界の呼吸器疾患治療薬市場で利用可能な主要機会を明らかにし、プレイヤーが市場で確固たる地位を獲得できるよう支援する素晴らしい試みを行っています。本レポートの購入者は、世界の呼吸器疾患治療薬市場の全体規模(売上高)を含む、検証済みで信頼できる市場予測にアクセスすることができます。
全体として、本レポートは、プレイヤーが競合他社に対する競争力を獲得し、世界の呼吸器疾患治療薬市場における持続的な成功を確実にするために使用できる効果的なツールであることが証明されています。本レポートで提供されるすべての調査結果、データ、情報は、信頼できる情報源の助けを借りて検証され、再確認されています。本レポートを執筆したアナリストは、世界の呼吸器疾患薬市場を詳細に調査するため、独自の業界最高水準の調査・分析アプローチを採用しています。

世界の呼吸器疾患用薬剤の範囲と市場規模
呼吸器障害治療薬市場は、プレイヤー別、地域(国)別、タイプ別、用途別に分類されています。呼吸器疾患薬の世界市場におけるプレイヤー、ステークホルダー、その他の参加者は、このレポートを強力なリソースとして利用することで、優位に立つことができるでしょう。セグメント別分析では、2017年から2028年までのタイプ別、アプリケーション別の収益と予測に焦点を当てます。

タイプ別セグメント
経口
経鼻
注射器
用途別セグメント
病院
小売店

会社別
ノバルティス
サノフィ
テバ・ファーマシューティカル
メルク・アンド・カンパニー
大日本住友製薬
マイラン
アストラゼネカ
ベーリンガーインゲルハイムインターナショナル
バーテックス・ファーマシューティカルズ・インコーポレイテッド
ロシュ
グラクソ・スミスクライン

地域別
北米
米国
カナダ
欧州
ドイツ
フランス
イギリス
イタリア
ロシア
北欧諸国
その他の欧州地域
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア
ラテンアメリカ
メキシコ
ブラジル
ラテンアメリカの残りの地域
中近東・アフリカ
トルコ
サウジアラビア
UAE
MEAの残りの地域


ページTOPに戻る


目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Disorders Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oral
1.2.3 Nasal
1.2.4 Injectable
1.3 Market by Application
1.3.1 Global Respiratory Disorders Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Disorders Drugs Market Perspective (2017-2028)
2.2 Respiratory Disorders Drugs Growth Trends by Region
2.2.1 Respiratory Disorders Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Respiratory Disorders Drugs Historic Market Size by Region (2017-2022)
2.2.3 Respiratory Disorders Drugs Forecasted Market Size by Region (2023-2028)
2.3 Respiratory Disorders Drugs Market Dynamics
2.3.1 Respiratory Disorders Drugs Industry Trends
2.3.2 Respiratory Disorders Drugs Market Drivers
2.3.3 Respiratory Disorders Drugs Market Challenges
2.3.4 Respiratory Disorders Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Disorders Drugs Players by Revenue
3.1.1 Global Top Respiratory Disorders Drugs Players by Revenue (2017-2022)
3.1.2 Global Respiratory Disorders Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Respiratory Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Respiratory Disorders Drugs Revenue
3.4 Global Respiratory Disorders Drugs Market Concentration Ratio
3.4.1 Global Respiratory Disorders Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Disorders Drugs Revenue in 2021
3.5 Respiratory Disorders Drugs Key Players Head office and Area Served
3.6 Key Players Respiratory Disorders Drugs Product Solution and Service
3.7 Date of Enter into Respiratory Disorders Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Disorders Drugs Breakdown Data by Type
4.1 Global Respiratory Disorders Drugs Historic Market Size by Type (2017-2022)
4.2 Global Respiratory Disorders Drugs Forecasted Market Size by Type (2023-2028)
5 Respiratory Disorders Drugs Breakdown Data by Application
5.1 Global Respiratory Disorders Drugs Historic Market Size by Application (2017-2022)
5.2 Global Respiratory Disorders Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Respiratory Disorders Drugs Market Size (2017-2028)
6.2 North America Respiratory Disorders Drugs Market Size by Type
6.2.1 North America Respiratory Disorders Drugs Market Size by Type (2017-2022)
6.2.2 North America Respiratory Disorders Drugs Market Size by Type (2023-2028)
6.2.3 North America Respiratory Disorders Drugs Market Share by Type (2017-2028)
6.3 North America Respiratory Disorders Drugs Market Size by Application
6.3.1 North America Respiratory Disorders Drugs Market Size by Application (2017-2022)
6.3.2 North America Respiratory Disorders Drugs Market Size by Application (2023-2028)
6.3.3 North America Respiratory Disorders Drugs Market Share by Application (2017-2028)
6.4 North America Respiratory Disorders Drugs Market Size by Country
6.4.1 North America Respiratory Disorders Drugs Market Size by Country (2017-2022)
6.4.2 North America Respiratory Disorders Drugs Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Respiratory Disorders Drugs Market Size (2017-2028)
7.2 Europe Respiratory Disorders Drugs Market Size by Type
7.2.1 Europe Respiratory Disorders Drugs Market Size by Type (2017-2022)
7.2.2 Europe Respiratory Disorders Drugs Market Size by Type (2023-2028)
7.2.3 Europe Respiratory Disorders Drugs Market Share by Type (2017-2028)
7.3 Europe Respiratory Disorders Drugs Market Size by Application
7.3.1 Europe Respiratory Disorders Drugs Market Size by Application (2017-2022)
7.3.2 Europe Respiratory Disorders Drugs Market Size by Application (2023-2028)
7.3.3 Europe Respiratory Disorders Drugs Market Share by Application (2017-2028)
7.4 Europe Respiratory Disorders Drugs Market Size by Country
7.4.1 Europe Respiratory Disorders Drugs Market Size by Country (2017-2022)
7.4.2 Europe Respiratory Disorders Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Disorders Drugs Market Size (2017-2028)
8.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Type
8.2.1 Asia-Pacific Respiratory Disorders Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Respiratory Disorders Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Respiratory Disorders Drugs Market Size by Application
8.3.1 Asia-Pacific Respiratory Disorders Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Respiratory Disorders Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Respiratory Disorders Drugs Market Size by Region
8.4.1 Asia-Pacific Respiratory Disorders Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Respiratory Disorders Drugs Market Size (2017-2028)
9.2 Latin America Respiratory Disorders Drugs Market Size by Type
9.2.1 Latin America Respiratory Disorders Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Respiratory Disorders Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Respiratory Disorders Drugs Market Share by Type (2017-2028)
9.3 Latin America Respiratory Disorders Drugs Market Size by Application
9.3.1 Latin America Respiratory Disorders Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Respiratory Disorders Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Respiratory Disorders Drugs Market Share by Application (2017-2028)
9.4 Latin America Respiratory Disorders Drugs Market Size by Country
9.4.1 Latin America Respiratory Disorders Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Respiratory Disorders Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Disorders Drugs Market Size (2017-2028)
10.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Type
10.2.1 Middle East & Africa Respiratory Disorders Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Respiratory Disorders Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Respiratory Disorders Drugs Market Size by Application
10.3.1 Middle East & Africa Respiratory Disorders Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Respiratory Disorders Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Respiratory Disorders Drugs Market Size by Country
10.4.1 Middle East & Africa Respiratory Disorders Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Respiratory Disorders Drugs Introduction
11.1.4 Novartis Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.1.5 Novartis Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Respiratory Disorders Drugs Introduction
11.2.4 Sanofi Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.2.5 Sanofi Recent Developments
11.3 Teva Pharmaceutical
11.3.1 Teva Pharmaceutical Company Details
11.3.2 Teva Pharmaceutical Business Overview
11.3.3 Teva Pharmaceutical Respiratory Disorders Drugs Introduction
11.3.4 Teva Pharmaceutical Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.3.5 Teva Pharmaceutical Recent Developments
11.4 Merck & Co.
11.4.1 Merck & Co. Company Details
11.4.2 Merck & Co. Business Overview
11.4.3 Merck & Co. Respiratory Disorders Drugs Introduction
11.4.4 Merck & Co. Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.4.5 Merck & Co. Recent Developments
11.5 Sumitomo Dainippon Pharma
11.5.1 Sumitomo Dainippon Pharma Company Details
11.5.2 Sumitomo Dainippon Pharma Business Overview
11.5.3 Sumitomo Dainippon Pharma Respiratory Disorders Drugs Introduction
11.5.4 Sumitomo Dainippon Pharma Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.5.5 Sumitomo Dainippon Pharma Recent Developments
11.6 Mylan
11.6.1 Mylan Company Details
11.6.2 Mylan Business Overview
11.6.3 Mylan Respiratory Disorders Drugs Introduction
11.6.4 Mylan Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.6.5 Mylan Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Respiratory Disorders Drugs Introduction
11.7.4 AstraZeneca Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.7.5 AstraZeneca Recent Developments
11.8 Boehringer Ingelheim International
11.8.1 Boehringer Ingelheim International Company Details
11.8.2 Boehringer Ingelheim International Business Overview
11.8.3 Boehringer Ingelheim International Respiratory Disorders Drugs Introduction
11.8.4 Boehringer Ingelheim International Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.8.5 Boehringer Ingelheim International Recent Developments
11.9 Vertex Pharmaceuticals Incorporated
11.9.1 Vertex Pharmaceuticals Incorporated Company Details
11.9.2 Vertex Pharmaceuticals Incorporated Business Overview
11.9.3 Vertex Pharmaceuticals Incorporated Respiratory Disorders Drugs Introduction
11.9.4 Vertex Pharmaceuticals Incorporated Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.9.5 Vertex Pharmaceuticals Incorporated Recent Developments
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Respiratory Disorders Drugs Introduction
11.10.4 Roche Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.10.5 Roche Recent Developments
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Respiratory Disorders Drugs Introduction
11.11.4 GlaxoSmithKline Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.11.5 GlaxoSmithKline Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

 

ページTOPに戻る


 

Summary

Market Analysis and Insights: Global Respiratory Disorders Drugs Market
The global Respiratory Disorders Drugs market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Oral accounting for % of the Respiratory Disorders Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.

China Respiratory Disorders Drugs market size is valued at US$ million in 2021, while the North America and Europe Respiratory Disorders Drugs are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Respiratory Disorders Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Respiratory Disorders Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Respiratory Disorders Drugs market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Respiratory Disorders Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Respiratory Disorders Drugs market.

Global Respiratory Disorders Drugs Scope and Market Size
Respiratory Disorders Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Respiratory Disorders Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type
Oral
Nasal
Injectable
Segment by Application
Hospital
Retail Pharmacy

By Company
Novartis
Sanofi
Teva Pharmaceutical
Merck & Co.
Sumitomo Dainippon Pharma
Mylan
AstraZeneca
Boehringer Ingelheim International
Vertex Pharmaceuticals Incorporated
Roche
GlaxoSmithKline

By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA



ページTOPに戻る


Table of Contents

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Respiratory Disorders Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oral
1.2.3 Nasal
1.2.4 Injectable
1.3 Market by Application
1.3.1 Global Respiratory Disorders Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Respiratory Disorders Drugs Market Perspective (2017-2028)
2.2 Respiratory Disorders Drugs Growth Trends by Region
2.2.1 Respiratory Disorders Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Respiratory Disorders Drugs Historic Market Size by Region (2017-2022)
2.2.3 Respiratory Disorders Drugs Forecasted Market Size by Region (2023-2028)
2.3 Respiratory Disorders Drugs Market Dynamics
2.3.1 Respiratory Disorders Drugs Industry Trends
2.3.2 Respiratory Disorders Drugs Market Drivers
2.3.3 Respiratory Disorders Drugs Market Challenges
2.3.4 Respiratory Disorders Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Respiratory Disorders Drugs Players by Revenue
3.1.1 Global Top Respiratory Disorders Drugs Players by Revenue (2017-2022)
3.1.2 Global Respiratory Disorders Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Respiratory Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Respiratory Disorders Drugs Revenue
3.4 Global Respiratory Disorders Drugs Market Concentration Ratio
3.4.1 Global Respiratory Disorders Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Respiratory Disorders Drugs Revenue in 2021
3.5 Respiratory Disorders Drugs Key Players Head office and Area Served
3.6 Key Players Respiratory Disorders Drugs Product Solution and Service
3.7 Date of Enter into Respiratory Disorders Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Respiratory Disorders Drugs Breakdown Data by Type
4.1 Global Respiratory Disorders Drugs Historic Market Size by Type (2017-2022)
4.2 Global Respiratory Disorders Drugs Forecasted Market Size by Type (2023-2028)
5 Respiratory Disorders Drugs Breakdown Data by Application
5.1 Global Respiratory Disorders Drugs Historic Market Size by Application (2017-2022)
5.2 Global Respiratory Disorders Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Respiratory Disorders Drugs Market Size (2017-2028)
6.2 North America Respiratory Disorders Drugs Market Size by Type
6.2.1 North America Respiratory Disorders Drugs Market Size by Type (2017-2022)
6.2.2 North America Respiratory Disorders Drugs Market Size by Type (2023-2028)
6.2.3 North America Respiratory Disorders Drugs Market Share by Type (2017-2028)
6.3 North America Respiratory Disorders Drugs Market Size by Application
6.3.1 North America Respiratory Disorders Drugs Market Size by Application (2017-2022)
6.3.2 North America Respiratory Disorders Drugs Market Size by Application (2023-2028)
6.3.3 North America Respiratory Disorders Drugs Market Share by Application (2017-2028)
6.4 North America Respiratory Disorders Drugs Market Size by Country
6.4.1 North America Respiratory Disorders Drugs Market Size by Country (2017-2022)
6.4.2 North America Respiratory Disorders Drugs Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Respiratory Disorders Drugs Market Size (2017-2028)
7.2 Europe Respiratory Disorders Drugs Market Size by Type
7.2.1 Europe Respiratory Disorders Drugs Market Size by Type (2017-2022)
7.2.2 Europe Respiratory Disorders Drugs Market Size by Type (2023-2028)
7.2.3 Europe Respiratory Disorders Drugs Market Share by Type (2017-2028)
7.3 Europe Respiratory Disorders Drugs Market Size by Application
7.3.1 Europe Respiratory Disorders Drugs Market Size by Application (2017-2022)
7.3.2 Europe Respiratory Disorders Drugs Market Size by Application (2023-2028)
7.3.3 Europe Respiratory Disorders Drugs Market Share by Application (2017-2028)
7.4 Europe Respiratory Disorders Drugs Market Size by Country
7.4.1 Europe Respiratory Disorders Drugs Market Size by Country (2017-2022)
7.4.2 Europe Respiratory Disorders Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Respiratory Disorders Drugs Market Size (2017-2028)
8.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Type
8.2.1 Asia-Pacific Respiratory Disorders Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Respiratory Disorders Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Respiratory Disorders Drugs Market Size by Application
8.3.1 Asia-Pacific Respiratory Disorders Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Respiratory Disorders Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Respiratory Disorders Drugs Market Size by Region
8.4.1 Asia-Pacific Respiratory Disorders Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Respiratory Disorders Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Respiratory Disorders Drugs Market Size (2017-2028)
9.2 Latin America Respiratory Disorders Drugs Market Size by Type
9.2.1 Latin America Respiratory Disorders Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Respiratory Disorders Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Respiratory Disorders Drugs Market Share by Type (2017-2028)
9.3 Latin America Respiratory Disorders Drugs Market Size by Application
9.3.1 Latin America Respiratory Disorders Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Respiratory Disorders Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Respiratory Disorders Drugs Market Share by Application (2017-2028)
9.4 Latin America Respiratory Disorders Drugs Market Size by Country
9.4.1 Latin America Respiratory Disorders Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Respiratory Disorders Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Respiratory Disorders Drugs Market Size (2017-2028)
10.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Type
10.2.1 Middle East & Africa Respiratory Disorders Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Respiratory Disorders Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Respiratory Disorders Drugs Market Size by Application
10.3.1 Middle East & Africa Respiratory Disorders Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Respiratory Disorders Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Respiratory Disorders Drugs Market Size by Country
10.4.1 Middle East & Africa Respiratory Disorders Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Respiratory Disorders Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Respiratory Disorders Drugs Introduction
11.1.4 Novartis Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.1.5 Novartis Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Respiratory Disorders Drugs Introduction
11.2.4 Sanofi Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.2.5 Sanofi Recent Developments
11.3 Teva Pharmaceutical
11.3.1 Teva Pharmaceutical Company Details
11.3.2 Teva Pharmaceutical Business Overview
11.3.3 Teva Pharmaceutical Respiratory Disorders Drugs Introduction
11.3.4 Teva Pharmaceutical Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.3.5 Teva Pharmaceutical Recent Developments
11.4 Merck & Co.
11.4.1 Merck & Co. Company Details
11.4.2 Merck & Co. Business Overview
11.4.3 Merck & Co. Respiratory Disorders Drugs Introduction
11.4.4 Merck & Co. Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.4.5 Merck & Co. Recent Developments
11.5 Sumitomo Dainippon Pharma
11.5.1 Sumitomo Dainippon Pharma Company Details
11.5.2 Sumitomo Dainippon Pharma Business Overview
11.5.3 Sumitomo Dainippon Pharma Respiratory Disorders Drugs Introduction
11.5.4 Sumitomo Dainippon Pharma Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.5.5 Sumitomo Dainippon Pharma Recent Developments
11.6 Mylan
11.6.1 Mylan Company Details
11.6.2 Mylan Business Overview
11.6.3 Mylan Respiratory Disorders Drugs Introduction
11.6.4 Mylan Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.6.5 Mylan Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Respiratory Disorders Drugs Introduction
11.7.4 AstraZeneca Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.7.5 AstraZeneca Recent Developments
11.8 Boehringer Ingelheim International
11.8.1 Boehringer Ingelheim International Company Details
11.8.2 Boehringer Ingelheim International Business Overview
11.8.3 Boehringer Ingelheim International Respiratory Disorders Drugs Introduction
11.8.4 Boehringer Ingelheim International Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.8.5 Boehringer Ingelheim International Recent Developments
11.9 Vertex Pharmaceuticals Incorporated
11.9.1 Vertex Pharmaceuticals Incorporated Company Details
11.9.2 Vertex Pharmaceuticals Incorporated Business Overview
11.9.3 Vertex Pharmaceuticals Incorporated Respiratory Disorders Drugs Introduction
11.9.4 Vertex Pharmaceuticals Incorporated Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.9.5 Vertex Pharmaceuticals Incorporated Recent Developments
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Respiratory Disorders Drugs Introduction
11.10.4 Roche Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.10.5 Roche Recent Developments
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Respiratory Disorders Drugs Introduction
11.11.4 GlaxoSmithKline Revenue in Respiratory Disorders Drugs Business (2017-2022)
11.11.5 GlaxoSmithKline Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療機器)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る